Skip to content
Pfizer Logo

Pfizer: Canada Launches First Gene Therapy Trial for Duchenne

May 4, 2021
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ground-breaking news, Canada has launched the first gene therapy trial for Duchenne muscular dystrophy.

Pfizer’s investigational gene therapy treatment is now recruiting in Canada at Children’s Hospital – London Health Sciences Centre in London, Ontario. This is an international study and their first site to open in North America. Boys with a confirmed diagnosis of Duchenne muscular dystrophy, 4-7 years old, and ambulatory (walking) may be eligible. If you are interested in learning more, please contact clinicaltrials.nmd4c@lhsc.on.ca.

“Our community remains hopeful for what the future may bring, and we are thankful for all the families that continue to donate their time and accept potential risks in the pursuit of advancing science and finding treatments for all boys and young men living with Duchenne.”

Nicola Worsfold, Director of Research and Advocacy at Defeat Duchenne Canada

This is an exciting milestone for Canadians living with Duchenne muscular dystrophy and hopefully the first of more to come.

Click the button below for more information about this study.

Related Articles